701 related articles for article (PubMed ID: 9240188)
1. Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate.
Nielsen JD; Gram J; Fabrin K; Holm-Nielsen A; Jespersen J
Br J Urol; 1997 Jul; 80(1):105-10. PubMed ID: 9240188
[TBL] [Abstract][Full Text] [Related]
2. Post-operative blood loss after transurethral prostatectomy is dependent on in situ fibrinolysis.
Nielsen JD; Gram J; Holm-Nielsen A; Fabrin K; Jespersen J
Br J Urol; 1997 Dec; 80(6):889-93. PubMed ID: 9439403
[TBL] [Abstract][Full Text] [Related]
3. Fibrinolysis: the key to new pathogenetic mechanisms.
Zorio E; Gilabert-Estellés J; España F; Ramón LA; Cosín R; Estellés A
Curr Med Chem; 2008; 15(9):923-9. PubMed ID: 18473800
[TBL] [Abstract][Full Text] [Related]
4. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
5. Relationship of fibrinolysis and platelet function to bleeding after cardiopulmonary bypass.
Ray MJ; Marsh NA; Hawson GA
Blood Coagul Fibrinolysis; 1994 Oct; 5(5):679-85. PubMed ID: 7865673
[TBL] [Abstract][Full Text] [Related]
6. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
7. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.
van Hinsbergh VW; Bauer KA; Kooistra T; Kluft C; Dooijewaard G; Sherman ML; Nieuwenhuizen W
Blood; 1990 Dec; 76(11):2284-9. PubMed ID: 1701665
[TBL] [Abstract][Full Text] [Related]
8. [Tissue plasminogen activator, its inhibitor and other parameters of fibrinolysis in blood of patients operated for mild hypertrophy of the prostate].
Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F; Cwiklińska-Jurkowska M
Pol Tyg Lek; 1992 Dec 7-14; 47(49-50):1096-7. PubMed ID: 1284828
[TBL] [Abstract][Full Text] [Related]
9. Hyperfibrinolysis in hepatosplenic schistosomiasis.
el-Bassiouni NE; el Bassiouny AE; el-Khayat HR; Akl MM; Omran SA
J Clin Pathol; 1996 Dec; 49(12):990-3. PubMed ID: 9038736
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
[TBL] [Abstract][Full Text] [Related]
11. The release of plasminogen activators (t-PA and u-PA) and plasminogen activator inhibitor (PAI-1) after venous stasis.
Falkon L; Garí M; Borrell M; Fontcuberta J
Blood Coagul Fibrinolysis; 1992 Feb; 3(1):33-8. PubMed ID: 1623118
[TBL] [Abstract][Full Text] [Related]
12. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance.
Keijer J; Linders M; van Zonneveld AJ; Ehrlich HJ; de Boer JP; Pannekoek H
Blood; 1991 Jul; 78(2):401-9. PubMed ID: 1712649
[TBL] [Abstract][Full Text] [Related]
13. Physical activity status and adverse age-related differences in coagulation and fibrinolytic factors in women.
DeSouza CA; Jones PP; Seals DR
Arterioscler Thromb Vasc Biol; 1998 Mar; 18(3):362-8. PubMed ID: 9514404
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitors type 1 and type 2 and plasminogen activators in amniotic fluid during pregnancy.
Estellés A; Gilabert J; Andrés C; España F; Aznar J
Thromb Haemost; 1990 Oct; 64(2):281-5. PubMed ID: 2125378
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolytic Dysregulation in Total Joint Arthroplasty Patients: Potential Clinical Implications.
Guler N; Burleson A; Syed D; Banos A; Hopkinson W; Hoppensteadt D; Rees H; Fareed J
Clin Appl Thromb Hemost; 2016 May; 22(4):372-6. PubMed ID: 26207021
[TBL] [Abstract][Full Text] [Related]
17. Complexing of tissue plasminogen activator with PAI-1, alpha 2-macroglobulin, and C1-inhibitor: studies in patients with defibrination and a fibrinolytic state after electroshock or complicated labor.
Bennett B; Croll A; Ferguson K; Booth NA
Blood; 1990 Feb; 75(3):671-6. PubMed ID: 1688722
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
[TBL] [Abstract][Full Text] [Related]
19. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
Vaziri ND; Gonzales EC; Shayestehfar B; Barton CH
J Lab Clin Med; 1994 Jul; 124(1):118-24. PubMed ID: 7518491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
